DK200900284A - Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base - Google Patents

Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base Download PDF

Info

Publication number
DK200900284A
DK200900284A DKPA200900284A DKPA200900284A DK200900284A DK 200900284 A DK200900284 A DK 200900284A DK PA200900284 A DKPA200900284 A DK PA200900284A DK PA200900284 A DKPA200900284 A DK PA200900284A DK 200900284 A DK200900284 A DK 200900284A
Authority
DK
Denmark
Prior art keywords
active pharmaceutical
tablet according
melting
water
soluble filler
Prior art date
Application number
DKPA200900284A
Other languages
English (en)
Inventor
Dancer Robert James
Petersen Hans
Nielsen Ole
Rock Michael Harold
Liljegren Ken
Eliassen Helle
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200900284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Priority to DKPA200900284A priority Critical patent/DK200900284A/da
Publication of DK200900284A publication Critical patent/DK200900284A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende opfindelse angår en smeltetablet, der har en hårdhed på mindst 22 N og en oral desintegrationstid på mindre end 120 s, og som indeholder en aktiv farmaceutisk bestanddel adsorberet på et vandopløseligt fyldstof, hvor den aktive farmaceutiske bestanddel har et smeltepunkt i området 40-1 00 °C, såvel som en fremgangsmåde til fremstilling af en sådan smeltetablet.

Claims (11)

1. Smeltetablet, der har en hårdhed på mindst 22 N og en oral desintegrationstid på mindre end 120 s, og som omfatter en aktiv farmaceutisk bestanddel adsorberet på et vandopløseligt fyldstof, ét eller flere desintegrationsmidler og eventuelt yderligere vandopløseligt fyldstof, hvor den aktive farmaceutiske bestanddel har et smeltepunkt i området 40-100 °C.
2. Smeltetablet ifølge krav 1, kendetegnet ved, at den aktive farmaceutiske bestanddel har et smeltepunkt i området 40-90 °C.
3. Smeltetablet ifølge krav 1 eller 2, kendetegnet ved, at den aktive farmaceutiske bestanddel er valgt fra gruppen bestående af escitalopram, ethosuximid, trimethadion, chlorambucil, disulfiram, fenofibrat, guaifenesin, lomustin, carisoprodol og perphenazin.
4. Smeltetablet ifølge krav 3, kendetegnet ved, at den aktive farmaceutiske bestanddel er escitalopram.
5. Smeltetablet ifølge et hvilket som helst af kravene 1-4, kendetegnet ved, at det vandopløselige fyldstof er valgt fra gruppen bestående af monosaccharider, disaccharider, sukkeralkoholer og polysaccharider.
6. Smeltetablet ifølge krav 5, kendetegnet ved, at det vandopløselige fyldstof er valgt fra gruppen bestående af mannitol, sorbitol, glucose, mannose og lactose.
7. Smeltetablet ifølge et hvilket som helst af kravene 1-6, kendetegnet ved, at den har en hårdhed på mindst 22 N.
8. Smeltetablet ifølge et hvilket som helst af kravene 1-7, kendetegnet ved, at den har en oral desintegrationstid på mindre end 60 s.
9. Smeltetablet ifølge et hvilket som helst af kravene 1-8, kendetegnet ved, at desintegrationsmidlerne er valgt fra gruppen bestående af mi kro krysta I li nsk cellulose, natriumstivelsesglycolat, croscarmellose-natrium, crospovidon og povidon.
10. Smeltetablet ifølge et hvilket som helst af kravene 1-9, kendetegnet ved, at den har en slidstyrke på ikke mere end 1 %.
11. Fremgangsmåde til fremstilling af en smeltetablet ifølge et hvilket som helst af kravene 1-10, der omfatter: a) blanding af det vandopløselige fyldstof og den aktive farmaceutiske bestanddel ved en temperatur over, omkring eller lidt under den aktive farmaceutiske bestanddels smeltepunkt, hvorved den aktive farmaceutiske bestanddel adsorberes på det vandopløselige fyldstof; b) efterfulgt af afkøling til en temperatur under 40 °C; c) blanding af blandingen af den aktive farmaceutiske bestanddel og det vandopløselige fyldstof med ét eller flere desintegrationsmidler og eventuelt andre hjælpestoffer og d) presning af blandingen til tabletter med en hårdhed på mindst 22 N.
DKPA200900284A 2005-06-22 2009-02-27 Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base DK200900284A (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DKPA200900284A DK200900284A (da) 2005-06-22 2009-02-27 Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200500912 2005-06-22
DK200500912 2005-06-22
DK200800075A DK200800075A (da) 2005-06-22 2008-01-21 Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase
DK200800075 2008-01-21
DKPA200900284A DK200900284A (da) 2005-06-22 2009-02-27 Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base
DK200900284 2009-02-27

Publications (1)

Publication Number Publication Date
DK200900284A true DK200900284A (da) 2009-02-27

Family

ID=37546630

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06742481.2T DK1896439T4 (da) 2005-06-22 2006-06-22 Krystallinsk base af escitalopram og orodispergerbare tabletter, der omfatter escitaloprambase
DK200800075A DK200800075A (da) 2005-06-22 2008-01-21 Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase
DKPA200900284A DK200900284A (da) 2005-06-22 2009-02-27 Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK06742481.2T DK1896439T4 (da) 2005-06-22 2006-06-22 Krystallinsk base af escitalopram og orodispergerbare tabletter, der omfatter escitaloprambase
DK200800075A DK200800075A (da) 2005-06-22 2008-01-21 Krystallinsk base af escitalopram og orodispergerbare tabletter indeholdende escitaloprambase

Country Status (39)

Country Link
EP (3) EP1896439B2 (da)
JP (5) JP4906852B2 (da)
KR (5) KR101340815B1 (da)
CN (2) CN101189220A (da)
AR (2) AR055062A1 (da)
AT (3) AT10983U1 (da)
AU (2) AU2006261452B2 (da)
BG (1) BG66086B1 (da)
BR (1) BRPI0612295A2 (da)
CA (2) CA2646780A1 (da)
CY (1) CY1112392T1 (da)
CZ (3) CZ300686B6 (da)
DE (2) DE602006019961D1 (da)
DK (3) DK1896439T4 (da)
EA (2) EA201001108A1 (da)
EE (1) EE00773U1 (da)
ES (2) ES2319073B1 (da)
FI (2) FI20077133L (da)
GB (2) GB2442160B (da)
HR (1) HRP20110093T4 (da)
HU (1) HUP0800135A3 (da)
IL (1) IL187454A0 (da)
IS (1) IS8705A (da)
LT (1) LT5550B (da)
LV (1) LV13677B (da)
MX (1) MX2007015328A (da)
MY (2) MY143239A (da)
NO (2) NO20080359L (da)
PL (2) PL384185A1 (da)
PT (1) PT1896439E (da)
RS (1) RS51575B2 (da)
SG (1) SG169358A1 (da)
SI (1) SI1896439T2 (da)
SK (1) SK500402007A3 (da)
TR (2) TR200708792T1 (da)
TW (2) TWI358407B (da)
UA (1) UA86536C2 (da)
WO (1) WO2006136169A2 (da)
ZA (2) ZA200711066B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2134325A2 (en) * 2007-03-01 2009-12-23 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
ES2569984T3 (es) 2010-07-23 2016-05-13 H. Lundbeck A/S Procedimiento para la purificación de sales farmacéuticamente aceptables de escitalopram
CN103360353A (zh) * 2013-08-07 2013-10-23 中国药科大学 草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ (1s)−1−[3−(ジメチルアミノ)プロピル]−1−(4−フルオロフェニル)−1,3−ジヒドロイソベンゾフラン−5−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN110711198B (zh) * 2018-07-12 2022-03-15 山东大学 D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko) 2019-04-09 2021-11-26 주식회사 라이트팜텍 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법
US20240100012A1 (en) * 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
JPH05222041A (ja) * 1992-02-13 1993-08-31 Mitsubishi Gas Chem Co Inc アデニン誘導体の精製法
ATE185266T1 (de) * 1994-01-27 1999-10-15 Univ Oklahoma Schnell auflösende orale darreichungsform
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AU4655597A (en) 1997-06-30 1999-01-19 Beloit Technologies, Inc. Method and apparatus for the high speed application of coating to a traveling paper web
WO1998019513A2 (en) 1997-07-08 1998-05-14 H. Lundbeck A/S Method for the preparation of citalopram
EP1042310B1 (en) 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
CA2424770A1 (en) * 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
KR20030042006A (ko) * 2000-10-16 2003-05-27 다이이찌 세이야꾸 가부시기가이샤 구강내 속붕괴성 의약 조성물 및 그의 제조방법
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
NL1017525C1 (nl) * 2000-12-22 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van zuiver Citalopram
ATE222899T1 (de) * 2000-12-28 2002-09-15 Lundbeck & Co As H Verfahren zur herstellung von reinem citalopram
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
BR0206164A (pt) * 2001-07-31 2003-10-28 Lundbeck & Co As H Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1517676A1 (en) * 2002-05-03 2005-03-30 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
UA80170C2 (en) 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
CN1510024A (zh) * 2002-12-24 2004-07-07 北京德众万全药物技术开发有限公司 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
WO2004100857A2 (en) * 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
WO2005049596A1 (en) * 2003-11-20 2005-06-02 Natco Pharma Limited A process for the preparation of high purity escitalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
AU2005218713B2 (en) * 2004-03-05 2009-11-19 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
EP1877394A1 (en) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Process for the preparation of escitalopram or its acid addition salts

Also Published As

Publication number Publication date
CZ2007898A3 (cs) 2008-01-23
BRPI0612295A2 (pt) 2011-01-04
AT11883U1 (de) 2011-06-15
GB2448834B (en) 2010-01-20
CZ299906B6 (cs) 2008-12-29
SG169358A1 (en) 2011-03-30
TWI358407B (en) 2012-02-21
MY143252A (en) 2011-04-15
KR20110084341A (ko) 2011-07-21
LT2008005A (en) 2008-10-27
BG110024A (bg) 2008-05-30
IS8705A (is) 2008-01-14
RS51575B (sr) 2011-08-31
UA86536C2 (ru) 2009-04-27
DK1896439T4 (da) 2015-01-12
IL187454A0 (en) 2008-02-09
CA2646780A1 (en) 2006-12-28
KR20080018191A (ko) 2008-02-27
SK500402007A3 (sk) 2008-05-06
GB2442160B (en) 2010-01-20
EP1896439A2 (en) 2008-03-12
AU2006261452B2 (en) 2010-02-04
CZ301286B6 (cs) 2009-12-30
TWI347942B (en) 2011-09-01
BG66086B1 (bg) 2011-03-31
GB0724557D0 (en) 2008-01-23
GB2448834A (en) 2008-10-29
EA019239B1 (ru) 2014-02-28
TW201130808A (en) 2011-09-16
TR200708792T1 (tr) 2008-05-21
AU2010200844A1 (en) 2010-04-01
EE00773U1 (et) 2008-10-15
HRP20110093T1 (hr) 2011-03-31
ES2319073A1 (es) 2009-05-01
PT1896439E (pt) 2011-02-15
ATE497500T1 (de) 2011-02-15
DE112006001619T5 (de) 2008-06-12
AT10983U1 (de) 2010-02-15
CN101189220A (zh) 2008-05-28
FI20077133A7 (fi) 2007-12-20
DE602006019961D1 (de) 2011-03-17
GB2442160A (en) 2008-03-26
JP5731957B2 (ja) 2015-06-10
GB0811164D0 (en) 2008-07-23
PL1896439T5 (pl) 2016-01-29
EA201001108A1 (ru) 2011-02-28
EP2325177A1 (en) 2011-05-25
JP2012072168A (ja) 2012-04-12
ZA200901698B (en) 2010-04-28
FI20077133L (fi) 2007-12-20
NO20101777L (no) 2008-01-18
ZA200711066B (en) 2009-07-29
SI1896439T2 (sl) 2014-12-31
LT5550B (lt) 2009-03-25
JP2009179635A (ja) 2009-08-13
KR20110033310A (ko) 2011-03-30
LV13677B (en) 2008-05-20
KR101340815B1 (ko) 2013-12-11
TW200740785A (en) 2007-11-01
DK200800075A (da) 2008-03-15
HRP20110093T4 (hr) 2015-02-27
JP4415056B2 (ja) 2010-02-17
CA2612827A1 (en) 2006-12-28
MX2007015328A (es) 2008-02-15
CZ300686B6 (cs) 2009-07-15
PL1896439T3 (pl) 2011-04-29
CN101928269A (zh) 2010-12-29
ES2356838T3 (es) 2011-04-13
EP2385044A1 (en) 2011-11-09
WO2006136169A3 (en) 2007-10-18
NO20080359L (no) 2008-01-18
CY1112392T1 (el) 2015-12-09
MY143239A (en) 2011-04-15
RS51575B2 (sr) 2018-02-28
JP2009046506A (ja) 2009-03-05
ES2356838T5 (es) 2015-01-26
HUP0800135A2 (en) 2008-06-30
TR201000625T1 (tr) 2010-03-22
ES2319073B1 (es) 2010-02-26
AU2006261452A1 (en) 2006-12-28
EP1896439B2 (en) 2014-10-15
FI20080548L (fi) 2008-10-07
WO2006136169A2 (en) 2006-12-28
JP4906852B2 (ja) 2012-03-28
EP1896439B1 (en) 2011-02-02
EA200800102A1 (ru) 2008-04-28
PL384185A1 (pl) 2008-06-23
AR079750A2 (es) 2012-02-15
HUP0800135A3 (en) 2009-01-28
KR20120064140A (ko) 2012-06-18
CA2612827C (en) 2010-11-30
JP2008546724A (ja) 2008-12-25
KR20100133023A (ko) 2010-12-20
FI20080548A7 (fi) 2008-10-07
DK1896439T3 (da) 2011-02-28
SI1896439T1 (sl) 2011-03-31
JP2009179634A (ja) 2009-08-13
AR055062A1 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
DK200900284A (da) Krystallinsk base af escitalopram og smeltetabletter indeholdende escitalopram base
RU2000123156A (ru) Быстро расщепляющаяся фармацевтическая лекарственная форма
UA105203C2 (ru) Твердая фармацевтическая композиция, которая содержит амлодипин и лозартан
RU2017133990A (ru) Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона
WO2007052289A3 (en) Novel dispersible tablet composition
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
UA106878C2 (uk) Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
JP2011037832A5 (da)
RU2012106139A (ru) Лекарственные формы цитрата железа (iii)
WO2003086362A3 (en) Method of stabilizing bupropion hydrochloride tablets
NO20074480L (no) Hurtig massefuktingsmetode for fremstilling av kalsium-inneholdende sammensetninger
RU2011112362A (ru) Твердые препаративные формы оспемифена
JP2022116267A (ja) トホグリフロジンを含有する固形製剤及びその製造方法
RU2008135718A (ru) Композиции клопидогреля бисульфата
FI3769765T3 (fi) Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
FR2819720B1 (fr) Nouveaux comprimes de fenofibrate
HRP20130108T1 (hr) Farmaceutski sastav koji sadrži aleglitazar
WO2009135950A3 (en) Process for preparing a tablet containing excipients
SI1773292T1 (sl) Hitro razgradljiva oralno disperzibilna farmacevtska oblika
RU2012121183A (ru) Фармацевтическая композиция для перорального введения
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
JP2017520628A5 (da)
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
JP2018127416A (ja) フェブキソスタット含有錠剤の製造方法
NZ628603A (en) Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen

Legal Events

Date Code Title Description
ATS Application withdrawn